Wegovy Pill Launch a Resounding Success, Says CEO

Novo Nordisk CEO Mike Doustdar has provided insights into the current state of the company's legacy business, acknowledging a slump attributed to price reductions and volume uptake dynamics. Doustdar highlighted the exceptionally strong initial uptake of the new Wegovy pill. The medication saw an impressive 170,000 patients begin treatment within its first four weeks of availability. This rapid adoption rate positions the Wegovy launch as one of the most successful pharmaceutical introductions in recent memory, showcasing significant market demand and patient interest. The company appears to be navigating its legacy business challenges while celebrating a major success with its new product.